What is the main purpose of the agreement with the North American Refractories Asbestos Personal Injury Settlement Trust?

The primary goal of the agreement is for Honeywell to make a one-time payment of $1.325 billion to the Trust, which would fully resolve and eliminate Honeywell's ongoing funding obligations related to past asbestos exposure claims from its former subsidiary, NARCO.

What are the conditions that need to be met for the settlement to be finalized?

The settlement is subject to several conditions, including approval by the United States Bankruptcy Court for the Western District of Pennsylvania, the Trust becoming a party to the agreement, and the NARCO Trust Advisory Committee (TAC) and the Future Claimants Representative (FCR) also becoming parties to the agreement. The agreement also has a termination date of March 31, 2023, unless extended.

How will this settlement impact Honeywell's financial statements?

If the settlement closes, Honeywell will remove its current NARCO reserve of $695 million (as of September 30, 2022) from its balance sheet and recognize a charge related to the settlement. However, the company has reaffirmed its 2022 financial guidance, assuming these accounting impacts do not affect the current year's financial statements.

Does Honeywell lose all rights to insurance recoveries related to these liabilities?

No, Honeywell will continue to have the right to collect proceeds from its insurance policies that cover its NARCO asbestos-related liabilities and will continue to recognize these insurance receivables.

HON/HONIV 8-K: Material Agreements

Summary

Honeywell International Inc. (HON) announced a significant development on November 18, 2022, entering into a definitive agreement to resolve its ongoing asbestos-related liabilities stemming from its former subsidiary, North American Refractories Company (NARCO). The company will make a one-time, lump sum payment of $1.325 billion to the North American Refractories Asbestos Personal Injury Settlement Trust. This payment, subject to certain conditions and court approvals, aims to completely eliminate Honeywell's future funding obligations to the Trust and its associated claims and operating expenses. This settlement represents a strategic move to de-risk Honeywell's balance sheet by removing its NARCO asbestos-related reserve and potentially simplifying its financial structure. While a charge will be recognized upon closing, the agreement provides for the release of Honeywell from all further obligations related to NARCO asbestos claims. The company reaffirmed its full-year and fourth-quarter 2022 financial guidance, assuming the accounting impacts of this settlement do not affect current year financial statements.

Key Highlights

1Honeywell entered into a definitive agreement to resolve all future funding obligations to the North American Refractories Asbestos Personal Injury Settlement Trust.
2A one-time lump sum payment of $1.325 billion (subject to adjustment) will be made to the Trust.
3The agreement aims to release Honeywell from all future obligations related to asbestos claims arising from North American Refractories Company (NARCO).
4The settlement requires approval from the U.S. Bankruptcy Court for the Western District of Pennsylvania and agreement from the NARCO Trust Advisory Committee (TAC) and Future Claimants Representative (FCR).
5Upon closing, Honeywell's existing NARCO reserve of $695 million as of September 30, 2022, will be removed from the balance sheet, and a settlement charge will be recognized.
6Honeywell retains the right to collect proceeds from its insurance policies related to these liabilities and will continue to recognize insurance receivables.
7The company reaffirmed its full-year and fourth-quarter 2022 financial guidance.

HONEYWELL INTERNATIONAL INC 8-K Report, Material Agreement (Nov 18, 2022)

Summary

Key Highlights

Frequently Asked Questions